Oppenheimer Asset Management Inc. boosted its stake in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 3.3% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 35,936 shares of the medical instruments supplier’s stock after acquiring an additional 1,156 shares during the period. Oppenheimer Asset Management Inc.’s holdings in West Pharmaceutical Services were worth $3,460,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Acrospire Investment Management LLC purchased a new position in shares of West Pharmaceutical Services in the 2nd quarter worth $113,000. Citigroup Inc. grew its stake in shares of West Pharmaceutical Services by 95.1% in the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 765 shares in the last quarter. Grandfield & Dodd LLC purchased a new position in shares of West Pharmaceutical Services in the 3rd quarter worth $201,000. Wolverine Trading LLC purchased a new position in shares of West Pharmaceutical Services in the 2nd quarter worth $200,000. Finally, Nomura Holdings Inc. purchased a new position in shares of West Pharmaceutical Services in the 2nd quarter worth $201,000. 93.28% of the stock is owned by institutional investors.

West Pharmaceutical Services, Inc. (WST) traded up $0.02 during mid-day trading on Monday, hitting $99.63. 331,500 shares of the company were exchanged, compared to its average volume of 361,982. West Pharmaceutical Services, Inc. has a 52-week low of $77.97 and a 52-week high of $103.36. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.87 and a current ratio of 2.59. The stock has a market cap of $7,397.82, a PE ratio of 42.94, a PEG ratio of 2.12 and a beta of 1.11.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, October 26th. The medical instruments supplier reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.53 by $0.14. West Pharmaceutical Services had a net margin of 12.12% and a return on equity of 14.47%. The firm had revenue of $398.20 million during the quarter, compared to analysts’ expectations of $386.02 million. During the same period in the previous year, the company earned $0.53 EPS. The firm’s revenue for the quarter was up 5.7% compared to the same quarter last year. equities research analysts predict that West Pharmaceutical Services, Inc. will post 2.76 earnings per share for the current fiscal year.

A number of equities analysts have commented on the stock. Stephens assumed coverage on shares of West Pharmaceutical Services in a research note on Tuesday, October 3rd. They issued an “equal weight” rating and a $99.00 price objective for the company. Zacks Investment Research raised shares of West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Wednesday, September 27th. Wells Fargo & Company lifted their price objective on shares of West Pharmaceutical Services from $105.00 to $112.00 and gave the stock an “outperform” rating in a research note on Friday, October 27th. Bank of America cut shares of West Pharmaceutical Services from a “buy” rating to a “neutral” rating and set a $98.00 price objective for the company. in a research note on Tuesday, October 17th. Finally, Jefferies Group raised shares of West Pharmaceutical Services from a “hold” rating to a “buy” rating and lifted their price objective for the stock from $96.00 to $115.00 in a research note on Friday, September 15th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $106.00.

TRADEMARK VIOLATION WARNING: This news story was first posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.watchlistnews.com/west-pharmaceutical-services-inc-wst-shares-bought-by-oppenheimer-asset-management-inc/1757919.html.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services, Inc. (NYSE:WST).

Institutional Ownership by Quarter for West Pharmaceutical Services (NYSE:WST)

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.